Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature

Abstract

Patients with thrombotic antiphospholipid syndrome (APS) require long-term anticoagulation due to the high-thrombotic recurrence risk. Vitamin K antagonists (VKA) have been traditionally considered the standard of care in thrombotic APS. Nevertheless, the risk of recurrence persists with VKA. There are publications considering different intensities of anticoagulation with VKA; however, the standard-intensity anticoagulation (international normalized ratio between 2.0 and 3.0) is the most recommended. Furthermore, there is no consensus on the role of antiplatelet treatment in thrombotic APS. Nonvitamin K antagonist oral anticoagulants (NOACs) have emerged as an alternative to VKA for many indications. There are, however, discrepancies regarding the management with NOACs in thrombotic APS. In this review, we update the different clinical trials with NOACs in venous, arterial, and microvascular thrombosis and suggest how these patients should be managed in agreement with the expert panels. Although scarce data are published regarding the current role of NOACs in thrombotic APS, the clinical trials failed to demonstrate noninferiority of NOACs compared with VKA, especially in patients with triple antiphospholipid antibodies positivity and/or arterial thrombosis. Single or double antiphospholipid positivity should be analyzed on a case-by-case basis. In addition, we focus on different areas of uncertainty that still remain in thrombotic APS and NOACs. To summarize, emerging clinical trials are needed to provide robust data on the management of thrombotic APS.

Keywords

thrombotic antiphospholipid syndrome - direct oral anticoagulants - vitamin K antagonists - recurrent thrombosis

Publication History

Article published online:
30 March 2023

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 2 Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines. Front Cardiovasc Med 2021; 8: 715878
• 3 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
• 4 Duarte-García A, Pham MM, Crowson CS. et al. The epidemiology of the antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019; 71 (09) 1545-1552
• 5 Kearon C, Parpia S, Spencer FA. et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 2018; 131 (19) 2151-2160
• 6 Miranda S, Park J, Le Gal G. et al. Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. J Thromb Haemost 2020; 18 (04) 926-930
• 7 Sciascia S, Sanna G, Khamashta MA. et al; APS Action. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis 2015; 74 (11) 2028-2033
• 8 Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65 (11) 1869-1873
• 9 Booth S, Burton K, Hunt B, Desborough M. Antiphospholipid syndrome and challenges with direct oral anticoagulants. Br J Hosp Med (Lond) 2020; 81 (05) 1-11
• 10 Sayar Z, Moll R, Isenberg D, Cohen H. Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. Thromb Res 2021; 198: 213-221
• 11 Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295 (09) 1050-1057
• 12 Pengo V, Ruffatti A, Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
• 13 Dufrost V, Risse J, Reshetnyak T. et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17 (10) 1011-1021
• 14 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
• 15 Finazzi G, Marchioli R, Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3 (05) 848-853
• 16 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
• 17 Giarretta I, Ageno W, Dentali F. Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome. Haematologica 2022; 107 (11) 2737-2741
• 18 Bala MM, Celinska-Lowenhoff M, Szot W. et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2020; 10 (10) CD012169
• 19 Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7 (01) 15-18
• 20 Cohen H, Cuadrado MJ, Erkan D. et al. 16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Lupus 2020; 29 (12) 1571-1593
• 21 Ohnishi N, Fujieda Y, Hisada R. et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology (Oxford) 2019; 58 (06) 969-974
• 22 Yamazaki M, Kadohira Y, Maekawa M. et al. Combined antiplatelet agents might help prevent arterial thrombosis in antiphospholipid syndrome. J Thromb Haemost 2009; 7 (Suppl. 02) 720-721
• 23 Aibar J, Schulman S. Arterial thrombosis in patients with antiphospholipid syndrome: a review and meta-analysis. Semin Thromb Hemost 2021; 47 (Suppl. 06) 709-723
• 24 Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115 (03) 672-678
• 25 Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost 2021; 19 (04) 892-908
• 26 Registry on augmented antithrombotic treatment regimens for patients with arterial thrombotic APS. ClinicalTrials.gov Identifier: NCT05649394
• 27 Zuily S, Cohen H, Isenberg D. et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020; 18 (09) 2126-2137
• 28 Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M. British Society for Haematology Haemostasis and Thrombosis Taskforce. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol 2020; 189 (02) 212-215
• 29 Cohen H, Hunt BJ, Efthymiou M. et al; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (09) e426-e436
• 30 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
• 31 Legault K, Blostein M, Carrier M. et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud 2020; 6: 1-7
• 32 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
• 33 Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomized, controlled, open-label, phase II/III, non-inferiority trial. ClinicalTrials.gov Identifier: NCT03684564
• 34 Ortel TL, Meleth S, Catellier D. et al. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: a systematic review and meta-analysis. J Thromb Haemost 2020; 18 (09) 2274-2286
• 35 Woller SC, Stevens SM, Kaplan D. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6 (06) 1661-1670
• 36 Cervera R, Serrano R, Pons-Estel GJ. et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
• 37 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
• 38 Siddique S, Risse J, Canaud G, Zuily S. Vascular manifestations in antiphospholipid syndrome (APS): is APS a thrombophilia or a vasculopathy?. Curr Rheumatol Rep 2017; 19 (10) 64
• 39 Carlin S, Eikelboom JW. Direct oral anticoagulant dose selection: challenging cases. J Thromb Haemost 2021; 19 (11) 2680-2686
• 40 Trujillo-Santos J, Di Micco P, Dentali F. et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
• 41 Eikelboom JW, Connolly SJ, Brueckmann M. et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
• 42 Pfrepper C, Behrendt LC, Bönigk H. et al. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA. Int J Lab Hematol 2022; 44 (01) 193-201
• 43 Moisa SM, Trandafir LM, Brinza C. et al. Current antithrombotic therapy strategies in children with focus on off-label direct oral anticoagulants: a narrative review. Children (Basel) 2022; 9 (07) 1093
• 44 Goldhaber SZ, Eriksson H, Kakkar A. et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vasc Med 2016; 21 (06) 506-514
• 45 Pharmacovigilance Risk Assessment Committee (PRAC). Accessed April 8, 2019 at: https://ema.europa.eu/en/documents/prac-recommendation/prac-recommendation-signals-adopted-8-11-april-2019-prac-meeting
• 46 Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect-and-direct -acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a coagulation reference laboratory. Am J Clin Pathol 2017; 147 (06) 632-640
• 47 Favaloro EJ. The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA). Am J Hematol 2019; 94 (11) 1290-1296
• 48 Ząbczyk M, Kopytek M, Natorska J, Undas A. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. Clin Chem Lab Med 2019; 57 (09) 1374-1381
• 49 Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015; 13 (07) 1264-1273
• 50 Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost 2022; 6 (02) e12676
• 51 Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020; 18 (07) 1569-1575